300832 ShenZhen New Industries Biomedical Engineering
- 77.83
- +0.91+1.18%
ShenZhen New Industries Biomedical Engineering News
New Industries (300832.SZ) plans to pay $10 for every 10 shares in 2023, excluding interest on May 15
New Industry (300832.SZ) announced that the company plans to pay 10.00 for every 10 shares to all shareholders in 2023...
A Look At The Intrinsic Value Of Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832)
Key Insights The projected fair value for Shenzhen New Industries Biomedical Engineering is CN¥79.38 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥70.70 suggests Shenzhen New I
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 93.36 Yuan From 98.15 Yuan, Keeps at Buy
04:55 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 93.36 Yuan From 98.15 Yuan, Keeps at Buy
New Industries (300832.SZ) announced first-quarter results, net profit of 426 million yuan, up 20.04% year on year
New Industries (300832.SZ) released its report for the first quarter of 2024. The company achieved operating income of 1 during the period...
New Industries (300832.SZ) obtained two medical device registration certificates
Zhitong Finance App News, New Industry (300832.SZ) announced that the company has received 2 “Medical Device Registration Certificates” issued by the Guangdong Drug Administration. The product names are: anti-RO-52 antibody IgG test kit (magnetic particle chemiluminescence method) and ammonia test kit (glutamate dehydrogenase method).
Shenzhen New Industries Biomedical Engineering Gets Nod to Register Five Devices
Shenzhen New Industries Biomedical Engineering (SHE:300832) received approval from the drug regulator of China's Guangdong Province to register five of its medical devices, according to the company's
Could The Market Be Wrong About Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832) Given Its Attractive Financial Prospects?
It is hard to get excited after looking at Shenzhen New Industries Biomedical Engineering's (SZSE:300832) recent performance, when its stock has declined 24% over the past month. However, a closer l
New Industries (300832.SZ) has obtained multiple medical device registration certificates
New Industry (300832.SZ) announcement. The company received 1 item from the State Drug Administration and 4 items from Guangdong Province...
New industry (300832.SZ): the domestic market target is 2,000 chemiluminescence instruments installed in 2024
Gelonghui, April 15 | New Industry (300832.SZ) said at an investor relations event that in the domestic market, the company will continue to adhere to the large machine installation strategy, further increase the proportion of large machines installed, and drive reagent sales through high-speed models and assembly line installations. The company's target for installing chemiluminescence instruments in the domestic market in 2024 is 2,000 units, and the total installed target for cooperative assembly lines (Thermo Fly, Hitachi) and the self-developed SATLARST8 assembly line is 100. In terms of end customers, the company will continue to promote the development of large-scale terminal hospital customers at level 3 and above, and improve reagent testing in level 3 hospitals
New industry (300832.SZ): The company's revenue growth rate is expected to be 25.56% in 2024
On April 15, Ge Longhui | New Industry (300832.SZ) said at an investor relations event that based on the company's business situation in 2023 and the forecast for the 2024 market situation, the company prepared the 2024 financial budget report, and the company's revenue growth rate for 2024 is expected to be 25.56%.
New industry (300832.SZ): MAGLUMI X3, a fully automatic chemiluminescence immunoanalyzer, obtained US FDA 510 (k) approval
New Industries (300832.SZ) issued an announcement. Recently, the company received the US Food and Drug Administration (English...
Shenzhen New Industries Biomedical Engineering's 2023 Profit Jumps 25%
Shenzhen New Industries Biomedical Engineering's (SHE:300832) attributable profit rose 25% to 1.65 billion yuan in 2023 from 1.33 billion yuan in 2022, according to a Friday filing with the Shenzhen S
New Industries (300832.SZ) announced its 2023 annual results, with net profit of 1,654 billion yuan, an increase of 24.53%
New Industries (300832.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 39...
Shenzhen New Industries Biomedical Engineering Co., Ltd.'s (SZSE:300832) Popularity With Investors Is Under Threat From Overpricing
There wouldn't be many who think Shenzhen New Industries Biomedical Engineering Co., Ltd.'s (SZSE:300832) price-to-earnings (or "P/E") ratio of 32.7x is worth a mention when the median P/E in China is
Cathay Pacific Junan: Target price of HK$7.59 for CRRC's “additional holdings” rating
Guotai Junan released a research report stating that it gave CRRC (01766) an “additional” rating. The estimated net profit for 2023-2025 is 122.10/137.19/15.235 billion yuan, corresponding EPS is 0.43/0.48/0.53 yuan, and the target price is HK$7.59. The company is a global leader in rail transit equipment. The “Large-scale Equipment Renewal Plan” accelerates the construction and renewal of the rail transit industry, is optimistic about the company's future performance growth, and drives improved profitability. Guotai Junan's main views are as follows: “Large-scale Equipment Renewal Plan” promotes the development of the industry and keeps up the road
New industry (300832.SZ) obtained a medical device registration certificate
New Industry (300832.SZ) announcement. The company received a “Medical Device...” issued by the Guangdong Drug Administration
Zhou Hongyi: The combination of big models and hardware will bring about a new industrial revolution. In the next five years, mobile phones will be the best hardware carriers
Sina Technology News On the evening of March 21, 360 Group founder Zhou Hongli appeared on the scene and delivered a speech at today's OnePlus Ace 3V product launch. He gave four major assertions of the big model and sixteen trends in the development of the AI industry in 2024. The four major assertions are: the big model is true intelligence, the big model is industrial revolutionary technology. AGI will cross the inflection point in the next 3-5 years, and all industries and products will be reshaped. The sixteen major trends are: the big open source model has exploded, and the big model will be everywhere in the future; the key to future AGI competition among major countries is the cloud supermodel, scale
New industry (300832.SZ): Obtain the right to use industrial land with parcel number G14304-0269 in Pingshan District, Shenzhen through an 80 million yuan auction
Gelonghui, March 13, 丨 New Industry (300832.SZ) announced that on March 13, 2024, the company participated in a public auction held by the People's Court of Longhua District of Shenzhen on the Jingdong Online Judicial Auction Platform to obtain the right to use industrial land with parcel number G14304-0269 in Pingshan District, Shenzhen with its own capital of RMB 80 million, and obtained the “Transaction Confirmation”. According to the relevant announcements, instructions, etc. of this auction, the company will deliver the transaction balance of the target object on time and complete the relevant formalities. The final transaction for the above parcel was auctioned by the People's Court of Longhua District, Shenzhen
Shenzhen New Industries Biomedical Engineering's (SZSE:300832) Returns On Capital Not Reflecting Well On The Business
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employed (ROC
Nomura Adjusts New Industries Biomedical Engineering's Price Target to 98.15 Yuan From 86.13 Yuan, Keeps at Buy
04:37 AM EDT, 03/12/2024 (MT Newswires) -- Nomura Adjusts New Industries Biomedical Engineering's Price Target to 98.15 Yuan From 86.13 Yuan, Keeps at Buy
Analysis
Price Target
No Data
